Denmark Recombinant Protein Therapeutics Cdmo Market Size & Outlook
Denmark recombinant protein therapeutics cdmo market, 2018-2030 (US$M)
Related Markets
Denmark recombinant protein therapeutics cdmo market highlights
- The Denmark recombinant protein therapeutics cdmo market generated a revenue of USD 455.4 million in 2023 and is expected to reach USD 1,099.9 million by 2030.
- The Denmark market is expected to grow at a CAGR of 13.4% from 2024 to 2030.
- In terms of segment, interferons was the largest revenue generating type in 2023.
- Growth Hormones is the most lucrative type segment registering the fastest growth during the forecast period.
Recombinant protein therapeutics cdmo market data book summary
| Market revenue in 2023 | USD 455.4 million |
| Market revenue in 2030 | USD 1,099.9 million |
| Growth rate | 13.4% (CAGR from 2023 to 2030) |
| Largest segment | Interferons |
| Fastest growing segment | Growth Hormones |
| Historical data | 2018 - 2022 |
| Base year | 2023 |
| Forecast period | 2024 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Growth Hormones, Interferons, Vaccines, Immunostimulating Agents |
| Key market players worldwide | Lonza Group Ltd, Catalent Inc, FUJIFILM Holdings Corp, WuXi Biologics (Cayman) Inc, Batavia Biosciences, Richter-Helm, Curia, HALIX, Biovian, Enzene Biosciences |
Other key industry trends
- In terms of revenue, Denmark accounted for 2.2% of the global recombinant protein therapeutics cdmo market in 2023.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In Europe, UK recombinant protein therapeutics cdmo market is projected to lead the regional market in terms of revenue in 2030.
- Germany is the fastest growing regional market in Europe and is projected to reach USD 2,892.8 million by 2030.
Interferons was the largest segment with a revenue share of 21.39% in 2023. Horizon Databook has segmented the Denmark recombinant protein therapeutics cdmo market based on growth hormones, interferons, vaccines, immunostimulating agents covering the revenue growth of each sub-segment from 2018 to 2030.
The recombinant protein therapeutics CDMO market in Denmark is expected to grow over the forecast period. Growth in the market can be attributed to the rising focus on core competencies, such as R&D, which is expected to drive the need for recombinant protein therapeutics. Favorable initiatives such as investment & partnerships are fueling market growth.
For instance, in May 2023, Fujifilm Dio synth Biotechnologies expanded its biologics production facility in Hillerod, Denmark, with the goal of transforming it into Europe's largest end-to-end CDMO for large-scale biologics. Moreover, the Denmark market is driven by factors such as the presence of well-established clinical infrastructure, high disease burden, and growing demand for newer treatment options.
According to World Cancer Research Fund International, Denmark has the highest cancer rate for women and men combined in 2023. Thus, the higher burden of diseases is expected to drive the number of new clinical research and hence support the demand for the development of effective biologics.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Recombinant Protein Therapeutics CDMO Market Scope
Recombinant Protein Therapeutics CDMO Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
Denmark recombinant protein therapeutics cdmo market size, by type, 2018-2030 (US$M)
Denmark Recombinant Protein Therapeutics CDMO Market Outlook Share, 2023 & 2030 (US$M)
Related industry reports
Related regional statistics
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
